The poor bioavailability and therapeutic response exhibited by conventional ophthalmic solutions due to rapid precorneal elimination of the drug may be overcome by the use of in situ gel-forming ophthalmic systems that are instilled as drops into the eye and undergo a sol–gel transition in the cul-de-sac. The present work describes development of an ophthalmic gel forming solution system of an agent brimonidine tartrate used in the treatment of glaucoma. Polyox WSR 301 was used as the gelling agent in combination with HPMC E50LV as a viscosity enhancing agent. The developed gel forming solution evaluated for Appearance, Clarity, pH and drug content, Rheological evaluation, In vitro drug release, Test for sterility, Stability study, Ocular irritation study and In vivo efficacy study (the elimination of brimonidine tartrate in tear and intraocular pressure-lowering effect). The developed formulation was therapeutically efficacious, stable, non-irritant and provide sustained release of the drug over an 8 hour. The developed system is thus a viable alternative to conventional brimonidine tartrate eye drops.
Loading....